Brief: Abbisko Cayman Egts IND Approval From China's NMPA For Initiation Of A Phase II Clinical Trial Of Absk011
19/10/2021 02:03
Oct 19 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* OBTAINED IND APPROVAL FROM CHINA'S NMPA FOR INITIATION OF
A
PHASE II CLINICAL TRIAL OF ABSK011
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly